Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

LEAVE THIS BLANK

Payment Information We accept all major credit cards

By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.
RETURN TO HOME
$599
Glucose Monitoring, Topics

Thoughts on New Dexcom G6 T2DM Basal-Only Study (MOBILE)

Here is a brief preview of this blast: A new trial (MOBILE) evaluating Dexcom’s G6 CGM vs. SMBG in 207 T2DM patients has been observed. With this trial, Dexcom appears to be moving beyond “intensive insulin-using T2DM” patients and into “basal-only,” which is a considerably larger market opportunity. Below, FENIX provides further details into the study design as well as thoughts on how Dexcom may utilize these results for expanding the G6 CGM eligible population.

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.